Welcome to the homepage of LBI-HTA !
The LBI-HTA is an acadmic non-profit institute and belongs to the Ludwig Boltzmann Society. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the LBI-HTA team.
We are pleased to introduce our new HSO report.
Biomarkers have become enormously important in oncology in recent years. As so-called “personalised medicine,” they support clinical decisions to assess patients, i.e., their tumours, with regard to response to therapies. Multi-gene panels (such as FoundationOne®Cdx) are just starting to be offered for comprehensive molecular-genetic tumour profiling, enabling the simultaneous analysis of a few to several hundred genetic alterations in disease genes. The health policy issue is whether multi-gene diagnostics using gene panels will lead to better clinical outcomes than conventional, single-biomarker stratification.
Public & philanthropic financial contribution to the development of new drugs: Methodology & 3 Case Studies
The term "access to medicines" was until a few years ago associated with the discussion surrounding cheaper (generic) vital drugs (HIV, tuberculosis, etc.) in developing countries. For some time, Western countries and institutions (OECD, European Commission, etc.) have also begun to focus on "access to medicines" in an attempt to counteract "unsustainable" drug prices.
Expenditure on research and development (R & D) is mostly used by manufacturers as a justification for high prices. The real - resource-consuming and high-risk - basic research takes place mainly in the public sector (in universities and corresponding publicly funded research institutions) instead. Little publicized knowledge on public spending, however, exists so far. The project objective is to collect information on public contributions to drug research and development and thus contribute to the discussion on "Return on Investment of Public Investment".
Diabetes mellitus is a rapidly increasing disease worldwide. In the Austrian Diabetes Report 2017, the number of people with diabetes mellitus in Austria is estimated at about 7 to 11%, with an assumed 30-35% not diagnosed. The—individually adapted—treatment of diabetes mellitus therefore aims to achieve freedom from symptoms and to prevent acute complications and serious secondary diseases. This project report examines whether screening in the general population is recommended in guidelines and, if so, what methods are used to recommend screening in subpopulations.
Publication: LBI-HTA Project report No. 118: http://eprints.hta.lbg.ac.at/1213/
Contact: Claudia Wild
Part I: Overview of screening and prevention programmes in other countries
Part II: Recommendations from evidence-based guidelines (guideline synopsis)
In Austria, the "Mutter-Kind-Pass” (the “mother-child pass") is a screening instrument for children up to the age of 5 years. There are currently no (universal) routine screenings in Austria for children and adolescents older than 6 years. In the present two-part report we researched and presented screening programmes in 9 countries and we identified evidence-based guidelines in guideline databases and via websites of relevant institutions and summarised their recommendations.
Publication: LBI-HTA Project report No. 106: http://eprints.hta.lbg.ac.at/1212/
Re-orientation of the Austrian parent-child preventive care programme. Part XI: Further development of the mother-child-pass: Screening recommendations of the expert working group for pregnancy, puerperium and early childhood (0-6 years)
In the process for the further development of the Austrian screening tool for pregnant women and children (“Mother-Child-Pass”), initiated by the Ministry of Health in 2014, after several reports conducted by the LBI-HTA, an interdisciplinary and multiprofessional expert working group formulated comprehensive (screening) recommendations for pregnancy, puerperium and childhood (0-6 years). The transparent and participatory process was finished in May 2018. The final report includes all protocols of the expert working group meetings as well as all submitted formal statements. Additionally, the recommendations were thematically structured by screening methods and by time.
Publication: LBI-HTA Project report No. 92: http://eprints.hta.lbg.ac.at/1163/
Contact: Inanna Reinsperger
Irreversible electroporation (IRE) is a non-thermal ablative process in which short but strong electric fields are generated using precisely placed needles and computer-controlled potential differences between these needles. In this way, pancreatic and liver tumors located near large blood vessels or other sensitive structures can be removed without damaging them.
There is insufficient evidence that IRE is more effective/safe or at least as effective/safe as the conventional standard of care (chemotherapy, chemoradiotherapy or palliative therapy) in the treatment of inoperable LAPC or that IRE is more effective/safe or at least as effective/safe as the conventional standard of care (TACE, sorafenib or palliative therapy) in the treatment of primary or secondary inoperable liver cancer that is not suitable for thermal ablation.
Publication: LBI-HTA Project report No. 119: http://eprints.hta.lbg.ac.at/1211/)
Contact: Eva Fuchs
We are pleased to introduce our new HSO report.
Custom-made or customisable 3D printed implants and cutting guides versus non- 3D printed standard implants and cutting guides for improving outcome in patients undergoing knee, maxillofacial, or cranial surgery
3D printed custom-made or customisable implants and cutting guides are currently most frequently applied in knee, maxillofacial, and cranial surgery. Evidence of very low or low quality shows significant differences in precision in terms of malalignment and deviation between 3D printed technology and standard instrumentation in knee arthroplasty. Evidence of higher quality is needed to validate these significant results and draw final conclusions. No firm conclusions can be made in mandibular reconstruction and cranioplasty, since no outcomes were significant in favour of either technology. No statements regarding long-term safety outcomes can be made.
Publication: LBI-HTA Projektbericht Nr. 117: http://eprints.hta.lbg.ac.at/1209/
Contact: Sabine Ettinger